Trilo Therapeutics

About:

Trilo Therapeutics is developing best-in-class peptide-drug conjugates that address the dose-limiting toxicity of current generation ADCs.

Website: http://trilotherapeutics.com/

Top Investors: National Science Foundation

Description:

Trilo Therapeutics, a San Francisco based company founded by biotech/pharma veterans, is developing best-in-class peptide-drug conjugates (PDC) that will address the dose-limiting toxicity of the current generation of ADCs. Trilo novel approach uses macrocyclic D-amino acid peptides to replace the antibody component of ADCs. Our conjugates: - provide superior tumor penetration than ADCs - reduce toxicity compared to traditional L-amino acid peptide-drug conjugates - are compatible with clinically validated payloads and radionuclides - open new treatment modalities based on a "fast in/fast out" mode of action